文献速递头颈外科

头颈癌免疫治疗中的患者报告结局

Patient-reported outcomes in immunotherapy for head and neck cancer.
PubMed 文献 · Head Neck · 2023-05-04

本研究为探索性研究,纳入开始接受免疫检查点抑制剂单药或联合西妥昔单抗治疗的头颈鳞状细胞癌患者,在治疗期间评估患者报告的毒性和生活质量。单药组48例、联合组38例的毒性随时间增加(p<0.05),总体生活质量从基线至12周改善、之后稳定或下降(p<0.05),两组间毒性指数与生活质量变化无差异。

要点

  • 单药组48例与联合组38例的患者报告毒性均随时间增加(p<0.05)。
  • 总体生活质量从基线至12周改善,之后稳定或下降(p<0.05)。
  • 联合组在免疫检查点抑制剂启动后18-20周和6个月时毒性指数评分显著高于单药组(p<0.05)。

核心结论

  • 尽管患者报告的毒性增加,免疫检查点抑制剂单药与联合西妥昔单抗治疗在头颈鳞状细胞癌患者中与相似的短暂生活质量改善、随后恶化相关。

研究设计与样本

  • 探索性研究,患者在首次接受检查点抑制剂治疗输注前被招募,并在治疗期间的门诊随访中完成检查点抑制剂毒性与生活质量测量。
  • 接受检查点抑制剂单药治疗的患者48例,接受联合治疗的患者38例。

主要发现

  • 单药组(n=48)或联合组(n=38)的毒性随时间增加(p<0.05)。
  • 总体生活质量从基线至12周改善,之后稳定或下降(p<0.05)。
  • 毒性指数或生活质量的变化在两组间无差异。
  • 联合组在免疫检查点抑制剂启动后18-20周和6个月时毒性指数评分显著高于单药组(p<0.05)。
  • 基线、6-8周(p=0.13)或3个月(p=0.09)评估时两组间无显著差异;联合组基线时报告的情绪健康优于单药组(p=0.04),基线及之后其他时间点生活质量无其他组间差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data about patient-reported outcomes (PROs) among patients with head and neck squamous cell carcinoma (HNSCC) treated with immune checkpoint inhibitors are sparse. Our exploratory study evaluated PROs in patients with HNSCC starting treatment with immune checkpoint inhibitor monotherapy or combination therapy with cetuximab. METHODS: Patients were recruited prior to receipt of their first checkpoint inhibitor therapy infusion. Participants completed measures of checkpoint inhibitor toxicities and quality of life (QOL) at on-treatment clinic visits. RESULTS: Among patients treated with checkpoint inhibitor monotherapy (n = 48) or combination therapy (n = 38) toxicity increased over time (p < 0.05), while overall QOL improved from baseline to 12 weeks, with stable or declining QOL thereafter (p < 0.05). There were no group differences in change in toxicity index or QOL. Toxicity index scores were significantly higher in the combination group at 18-20 weeks and 6 months post-initiation of immune checkpoint inhibitor (p < 0.05). There were no significant group differences at baseline, the 6-8 week (p = 0.13) or 3-month (p = 0.09) evaluations. The combination group reported better emotional well-being at baseline than the monotherapy group (p = 0.04), There were no other group differences QOL at baseline or later timepoints. CONCLUSIONS: Despite increasing patient-reported toxicity, checkpoint inhibitor monotherapy and combination therapy were associated with similar transient improvements, then worsening, of QOL in patients with HNSCC.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Kirtane K, Hoogland AI, Li X, et al. Patient-reported outcomes in immunotherapy for head and neck cancer. Head Neck. 2023. PMID: 37141438. doi:10.1002/hed.27388

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。